Predicting the risk of developing breast cancer is an important clinical tool to guide early intervention and tailoring personalized screening strategies. Early risk models have limited performance and recently machine learning-based analysis of mammogram images showed encouraging risk prediction effects. These models however are limited to the use of a single exam or tend to overlook nuanced breast tissue evolvement in spatial and temporal details of longitudinal imaging exams that are indicative of breast cancer risk. In this paper, we propose STA-Risk (Spatial and Temporal Asymmetry-based Risk Prediction), a novel Transformer-based model that captures fine-grained mammographic imaging evolution simultaneously from bilateral and longitudinal asymmetries for breast cancer risk prediction. STA-Risk is innovative by the side encoding and temporal encoding to learn spatial-temporal asymmetries, regulated by a customized asymmetry loss. We performed extensive experiments with two independent mammogram datasets and achieved superior performance than four representative SOTA models for 1- to 5-year future risk prediction. Source codes will be released upon publishing of the paper.

We explored the fractal and multifractal characteristics of breast mammogram micrographs to identify quantitative biomarkers associated with breast cancer progression. In addition to conventional fractal and multifractal analyses, we employed a recently developed fractal-functional distribution method, which transforms fractal measures into Gaussian distributions for more robust statistical interpretation. Given the sparsity of mammogram intensity data, we also analyzed how variations in intensity thresholds, used for binary transformations of the fractal dimension, follow unique trajectories that may serve as novel indicators of disease progression. Our findings demonstrate that fractal, multifractal, and fractal-functional parameters effectively differentiate between benign and cancerous tissue. Furthermore, the threshold-dependent behavior of intensity-based fractal measures presents distinct patterns in cancer cases. To complement these analyses, we applied the Inverse Participation Ratio (IPR) light localization technique to quantify structural disorder at the microscopic level. This multi-parametric approach, integrating spatial complexity and structural disorder metrics, offers a promising framework for enhancing the sensitivity and specificity of breast cancer detection.

Breast cancer is the most commonly occurring cancer worldwide. This cancer caused 670,000 deaths globally in 2022, as reported by the WHO. Yet since health officials began routine mammography screening in age groups deemed at risk in the 1980s, breast cancer mortality has decreased by 40% in high-income nations. Every day, a greater and greater number of people are receiving a breast cancer diagnosis. Reducing cancer-related deaths requires early detection and treatment. This paper compares two convolutional neural networks called ConvNeXT and EfficientNet to predict the likelihood of cancer in mammograms from screening exams. Preprocessing of the images, classification, and performance evaluation are main parts of the whole procedure. Several evaluation metrics were used to compare and evaluate the performance of the models. The result shows that ConvNeXT generates better results with a 94.33% AUC score, 93.36% accuracy, and 95.13% F-score compared to EfficientNet with a 92.34% AUC score, 91.47% accuracy, and 93.06% F-score on RSNA screening mammography breast cancer dataset.

We developed an artificial intelligence system (AIS) using multi-view multi-level convolutional neural networks for breast cancer detection, diagnosis, and BI-RADS categorization support in mammography. Twenty-four thousand eight hundred sixty-six breasts from 12,433 Asian women between August 2012 and December 2018 were enrolled. The study consisted of three parts: (1) evaluation of AIS performance in malignancy diagnosis; (2) stratified analysis of BI-RADS 3-4 subgroups with AIS; and (3) reassessment of BI-RADS 0 breasts with AIS assistance. We further evaluate AIS by conducting a counterbalance-designed AI-assisted study, where ten radiologists read 1302 cases with/without AIS assistance. The area under the receiver operating characteristic curve (AUC), sensitivity, specificity, accuracy, and F1 score were measured. The AIS yielded AUC values of 0.995, 0.933, and 0.947 for malignancy diagnosis in the validation set, testing set 1, and testing set 2, respectively. Within BI-RADS 3-4 subgroups with pathological results, AIS downgraded 83.1% of false-positives into benign groups, and upgraded 54.1% of false-negatives into malignant groups. AIS also successfully assisted radiologists in identifying 7 out of 43 malignancies initially diagnosed with BI-RADS 0, with a specificity of 96.7%. In the counterbalance-designed AI-assisted study, the average AUC across ten readers significantly improved with AIS assistance (p = 0.001). AIS can accurately detect and diagnose breast cancer on mammography and further serve as a supportive tool for BI-RADS categorization. An AI risk assessment tool employing deep learning algorithms was developed and validated for enhancing breast cancer diagnosis from mammograms, to improve risk stratification accuracy, particularly in patients with dense breasts, and serve as a decision support aid for radiologists. The false positive and negative rates of mammography diagnosis remain high. The AIS can yield a high AUC for malignancy diagnosis. The AIS is important in stratifying BI-RADS categorization.

Image segmentation plays a central role in computer vision applications such as medical imaging, industrial inspection, and environmental monitoring. However, evaluating segmentation performance can be particularly challenging when ground truth is not clearly defined, as is often the case in tasks involving subjective interpretation. These challenges are amplified by inter- and intra-observer variability, which complicates the use of human annotations as a reliable reference. To address this, we propose a novel validation framework-referred to as the three-blind validation strategy-that enables rigorous assessment of segmentation models in contexts where subjectivity and label variability are significant. The core idea is to have a third independent expert, blind to the labeler identities, assess a shuffled set of segmentations produced by multiple human annotators and/or automated models. This allows for the unbiased evaluation of model performance and helps uncover patterns of disagreement that may indicate systematic issues with either human or machine annotations. The primary objective of this study is to introduce and demonstrate this validation strategy as a generalizable framework for robust model evaluation in subjective segmentation tasks. We illustrate its practical implementation in a mammography use case involving dense tissue segmentation while emphasizing its potential applicability to a broad range of segmentation scenarios.

In the prognosis of breast cancer, the status of axillary lymph nodes (ALN) is critically important. While traditional axillary lymph node dissection (ALND) provides comprehensive information, it is associated with high risks. Sentinel lymph node biopsy (SLND), as an alternative, is less invasive but still poses a risk of overtreatment. In recent years, digital breast tomosynthesis (DBT) technology has emerged as a new precise diagnostic tool for breast cancer, leveraging its high detection capability for lesions obscured by dense glandular tissue. This multi-center study evaluates the feasibility of preoperative DBT-based radiomics, using tumor and peritumoral features, to predict ALN metastasis in breast cancer. We retrospectively collected DBT imaging data from 536 preoperative breast cancer patients across two centers. Specifically, 390 cases were from one Hospital, and 146 cases were from another Hospital. These data were assigned to internal training and external validation sets, respectively. We performed 3D region of interest (ROI) delineation on the cranio-caudal (CC) and mediolateral oblique (MLO) views of DBT images and extracted radiomic features. Using methods such as analysis of variance (ANOVA) and least absolute shrinkage and selection operator (LASSO), we selected radiomic features extracted from the tumor and its surrounding 3 mm, 5 mm, and 10 mm regions, and constructed a radiomic feature set. We then developed a combined model that includes the optimal radiomic features and clinical pathological factors. The performance of the combined model was evaluated using the area under the curve (AUC), and it was directly compared with the diagnostic results of radiologists. The results showed that the AUC of the radiomic features from the surrounding regions of the tumor were generally lower than those from the tumor itself. Among them, the Signature_{tuomor+10 mm} model performed best, achieving an AUC of 0.806 using a logistic regression (LR) classifier to generate the RadScore.The nomogram incorporating both Ki67 and RadScore demonstrated a slightly higher AUC (0.813) compared to the Signature_{tuomor+10 mm} model alone (0.806). By integrating relevant clinical information, the nomogram enhances potential clinical utility. Moreover, it outperformed radiologists' assessments in predictive accuracy, highlighting its added value in clinical decision-making. Radiomics based on DBT imaging of the tumor and surrounding regions can provide a non-invasive auxiliary tool to guide treatment strategies for ALN metastasis in breast cancer. Not applicable.

Identifying systemic disease with medical imaging studies may improve population health outcomes. Although the pathogenesis of peripheral arterial calcification and coronary artery calcification differ, breast arterial calcification (BAC) on mammography is associated with cardiovascular disease (CVD), a leading cause of death in women. While professional society guidelines on the reporting or management of BAC have not yet been established, and assessment and quantification methods are not yet standardized, the value of reporting BAC is being considered internationally as a possible indicator of subclinical CVD. Furthermore, artificial intelligence (AI) models are being developed to identify and quantify BAC on mammography, as well as to predict the risk of CVD. This review outlines studies evaluating the association of BAC and CVD, introduces the role of preventative cardiology in clinical management, discusses reasons to consider reporting BAC, acknowledges current knowledge gaps and barriers to assessing and reporting calcifications, and provides examples of how AI can be utilized to measure BAC and contribute to cardiovascular risk assessment. Ultimately, reporting BAC on mammography might facilitate earlier mitigation of cardiovascular risk factors in asymptomatic women.

Artificial intelligence (AI) studies show promise in enhancing accuracy and efficiency in mammographic screening programs worldwide. However, its integration into clinical workflows faces several challenges, including unintended errors, the need for professional training, and ethical concerns. Notably, specific frameworks for AI imaging in breast cancer screening are still lacking. This study aims to identify the challenges associated with implementing AI in breast screening programs and to apply the Consolidated Framework for Implementation Research (CFIR) to discuss a practical governance framework for AI in this context. Three electronic databases (PubMed, Embase, and MEDLINE) were searched using combinations of the keywords "artificial intelligence," "regulation," "governance," "breast cancer," and "screening." Original studies evaluating AI in breast cancer detection or discussing challenges related to AI implementation in this setting were eligible for review. Findings were narratively synthesized and subsequently mapped directly onto the constructs within the CFIR. A total of 1240 results were retrieved, with 20 original studies ultimately included in this systematic review. The majority (n=19) focused on AI-enhanced mammography, while 1 addressed AI-enhanced ultrasound for women with dense breasts. Most studies originated from the United States (n=5) and the United Kingdom (n=4), with publication years ranging from 2019 to 2023. The quality of papers was rated as moderate to high. The key challenges identified were reproducibility, evidentiary standards, technological concerns, trust issues, as well as ethical, legal, societal concerns, and postadoption uncertainty. By aligning these findings with the CFIR constructs, action plans targeting the main challenges were incorporated into the framework, facilitating a structured approach to addressing these issues. This systematic review identifies key challenges in implementing AI in breast cancer screening, emphasizing the need for consistency, robust evidentiary standards, technological advancements, user trust, ethical frameworks, legal safeguards, and societal benefits. These findings can serve as a blueprint for policy makers, clinicians, and AI developers to collaboratively advance AI adoption in breast cancer screening. PROSPERO CRD42024553889; https://tinyurl.com/mu4nwcxt.

Evaluate an Artificial Intelligence (AI) system in breast screening through stratified results across age, breast density, ethnicity and screening centres, from different UK regions. A large-scale retrospective study evaluating two variations of using AI as an independent second reader in double reading was executed. Stratifications were conducted for clinical and operational metrics. Data from 306 839 mammography cases screened between 2017 and 2021 were used and included three different UK regions.The impact on safety and effectiveness was assessed using clinical metrics: cancer detection rate and positive predictive value, stratified according to age, breast density and ethnicity. Operational impact was assessed through reading workload and recall rate, measured overall and per centre.Non-inferiority was tested for AI workflows compared with human double reading, and when passed, superiority was tested. AI interval cancer (IC) flag rate was assessed to estimate additional cancer detection opportunity with AI that cannot be assessed retrospectively. The AI workflows passed non-inferiority or superiority tests for every metric across all subgroups, with workload savings between 38.3% and 43.7%. The AI standalone flagged 41.2% of ICs overall, ranging between 33.3% and 46.8% across subgroups, with the highest detection rate for dense breasts. Human double reading and AI workflows showed the same performance disparities across subgroups. The AI integrations maintained or improved performance at all metrics for all subgroups while achieving significant workload reduction. Moreover, complementing these integrations with AI as an additional reader can improve cancer detection. The granularity of assessment showed that screening with the AI-system integrations was as safe as standard double reading across heterogeneous populations.